Table 3: Therapeutic approach according to the presence of cardiovascular disease.

Overall CV disease No CV disease P
Antithrombotic drugs
Antiplatelets (%) 14.2 44.6 8.2 0.0001
Anticoagulants (%)
VKA
DOACs
4.6
4.1
0.5
15.1
13.6
1.5
2.6
2.3
0.3
0.0001
0.0001
0.0001
Nonsteroidal anti-inflammatory drugs (%) 12.7 11.7 12.9 NS
Antihypertensive drugs
Number of antihypertensive drugs 1.7 ± 0.9 2.0 ± 1.0 1.6 ± 0.9 0.0001
Number of antihypertensive drugs
0
1
2
3
> 3

6.3
40.2
34.7
15.7
3.1

4.4
28.5
36.5
24.3
6.3

6.7
42.5
34.3
14.0
2.5
0.0001
ARB (%) 44.9 48.8 44.2 NS
Diuretics (%) 44.6 48.2 43.9 NS
ACEi (%) 36.6 32.3 37.5 0.044
Calcium channel blockers (%) 22.5 31.4 20.7 0.0001
Beta Blockers (%) 18.3 33.8 13.1 0.0001
Alpha blockers (%) 3.5 4.4 3.2 NS
Lipid lowering drugs
Number of lipid lowering drugs 0.7 ± 0.5 1.0 ± 0.5 0.7 ± 0.5 0.0001
Number of lipid lowering drugs
0
1
2
3

27.8
66.9
5.2
0.1

15.0
75.5
9.1
0.4

30.3
65.3
4.4
0
0.0001
Statins (%) 67.4 79.7 65.0 0.0001
Fibrates (%) 6.0 6.8 5.9 NS
Ezetimibe (%) 1.4 7.8 2.2 0.0001
Others (%) 0.8 0.6 0.8 NS
Antidiabetic drugs
Number of antidiabetic drugs 1.6 ± 0.9 1.5 ± 0.9 1.6 ± 0.9 NS
Number of antidiabetic drugs
0
1
2
3
4

10.3
41.1
33.8
12.2
2.6

8.4
45.8
32.2
11.2
2.4

10.7
40.2
34.1
12.4
2.6
NS
Metformin 75.0 67.3 76.5 0.011
Dipeptidyl peptidase 4 inhibitors 30.4 31.8 30.2 NS
Insulin 20.7 29.0 19.1 0.004
Sulfonylureas 14.5 11.2 15.2 NS
Glinides 4.6 4.7 4.6 NS
Sodium-glucose Cotransporter-2 inhibitors 4.2 3.3 4.4 NS
GLP-1 receptor agonists 3.0 3.7 2.9 NS
Thiazolidinediones 2.6 2.3 2.6 NS

CV: Cardiovascular; VKA: Vitamin K Antagonists; DOACs: Direct Oral Anticoagulants; ARB: Angiotensin Receptor Blockers; ACEi: Angiotensin Converting Enzyme inhibitors.